US 12,460,178 B2
Method of inducing or improving wound healing properties of mesenchymal stem cells
Toan Thang Phan, Singapore (SG); and Gavin Tan, Singapore (SG)
Assigned to Cellresearch Corporation Pte. Ltd., Singapore (SG)
Filed by Cellresearch Corporation Pte. Ltd., Singapore (SG)
Filed on Apr. 11, 2019, as Appl. No. 16/382,071.
Claims priority of provisional application 62/656,531, filed on Apr. 12, 2018.
Prior Publication US 2020/0325443 A1, Oct. 15, 2020
Prior Publication US 2021/0301252 A9, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/073 (2010.01); A61K 35/50 (2015.01); A61K 35/51 (2015.01)
CPC C12N 5/0605 (2013.01) [A61K 35/50 (2013.01); A61K 35/51 (2013.01); C12N 2501/12 (2013.01); C12N 2501/15 (2013.01); C12N 2501/165 (2013.01); C12N 2501/17 (2013.01)] 10 Claims
 
1. A method of inducing or improving wound healing properties of a mesenchymal stem cell population derived from umbilical cord, the method comprising cultivating the mesenchymal stem cell population in a culture medium comprising 55 to 65% (v/v) Dulbecco's modified Eagle's medium (DMEM), 5 to 15% (v/v) Ham's F12 Medium (F12), 15 to 30% (v/v) Medium 171 (M171) and 1 to 8% (v/v) Fetal Bovine Serum (FBS) in a bioreactor under conditions such that the mesenchymal stem cell population in said culture medium results in an increase in expression and/or secretion of at least three of Angiopoietin 1 (Ang-1), TGF-β1, VEGF, and HGF by the mesenchymal stem cell population relative to cultivation of said mesenchymal stem cell population in a reference culture medium that does not comprise all of DMEM, F12, M171, and FBS.